Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- Trial number:
-
NCT04699188
- Trial phase:
- 1, 2
- Study type:
- Targeted therapy, Biomarker
- Overall status:
- Recruiting
Study start date
Scientific title
Summary
Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapiesECOG Performance Status of 0 or 1 At least one measurable lesion as defined by RECIST 1.1 Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion
Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutationsSymptomatic brain metastases or known leptomeningeal disease Clinically significant cardiac disease or risk factors at screening A medical condition that results in increased photosensitivity Other protocol-defined inclusion/exclusion criteria may apply.